Introduction
The induction of strong cytolytic CD8 + T cell responses capable of killing transformed cells is considered vital for the success of therapeutic cancer vaccines 1 have increased the stability of IVT mRNAs to such extent protein expression can now be achieved for days after direct in vivo administration of the mRNA [4] [5] [6] . These breakthroughs have revolutionized the mRNA vaccination allowing direct injection of antigen encoding mRNA to be explored for the treatment of patients with prostate cancer, non-small lung cell carcinoma and melanoma [7] [8] [9] [10] [11] [12] [13] .
When applied directly in vivo, mRNA vaccines strongly benefit from wrapping the mRNA into nanosized carriers. Within this context, our group previously demonstrated that condensing mRNA into cationic lipoplexes increases the potency of the mRNA vaccine evoked T cell response by several orders of magnitude 14 . One of the typical hallmarks of IVT mRNAs condensed into nano-formulations is their capacity to elicit intense secretion of Type I interferons (IFNs) in murine and human DCs 14, 15 . Indeed, IVT mRNA appears to mimic viral RNA in its capacity to trigger a variety of cellular endosomal and cytosolic RNA sensors that all induce a signalling cascade culminating in the release of type I IFNs 14-17 .
Type I IFNs are highly pleiotropic cytokines that can either promote or inhibit T cell responses Cationic liposomes have been reported to increase T cell responses to mRNA encoded antigens 26 . In this study, liposomes composed of the cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOTAP) and the neutral helper lipid (DOPE) were used to condense mRNA into lipoplexes. Preliminary research was done to determine the nitrogen/phosphate ratio most suited for in vivo application and is shown as additional data (Fig. S1 ). We evaluated two N/P ratios that give yield to mRNA lipoplexes of similar size (± 300-400 nm) but opposite charge, namely lipoplexes at N/P1 had a negative zeta-potential of -18 mV and N/P10 lipoplexes displayed a positive charge of +32 mV (Figs. S1a,b). Further, we addressed mRNA lipoplexes of ratio N/P1 as most suited to yield high expression levels of the delivered mRNA ( Previously, we have demonstrated that DOTAP-based mRNA lipoplexes elicit strong type I IFN secretion upon incubation with bone marrow derived DCs in vitro 14 . To address to which extent mRNA lipoplexes would trigger type I IFNs in vivo upon subcutaneous injection, we used an IFN-β reporter mouse in which a firefly luciferase encoding sequence has been placed under the control of the IFN-β promoter (Fig. 1a ) 27 . As type I IFN production is regulated by self-enforcing feedforward loops, heterozygous reporter mice (IFN-β +/∆β-luc ) were used to allow signal amplification by early induced IFN-β. Mice were injected subcutaneously with respectively DOTAP liposomes (no mRNA), unformulated mRNA or mRNA lipoplexes. In vivo bioluminescence imaging revealed a strong induction of the IFN-β promoter to injection of naked mRNA and of mRNA lipoplexes, but not to liposomes without mRNA (Fig. 1b,c) . Strikingly, naked OVA mRNA elicited the most prominent induction of type I IFNs, clearly ). First, we addressed the effects of type I IFNs on the initial priming of antigen-specific T cells. To this end, CFSE labelled transgenic OVA-specific CD8 + T cells (OT-I T cells) were transferred to respectively wild type and Ifnar -/-mice, which were subsequently immunized with OVA mRNA lipoplexes. Four days post immunization, the draining popliteal lymph nodes were dissected and OT-I T cell proliferation was analysed by flow cytometry (Fig. 2a) . As shown in Fig. 2b , Ifnar -/-mice showed strongly elevated OT-I proliferation when compared to wild type mice. 
A c c e p t e d m a n u s c r i p t
Type I IFNs dampen cytolytic T cell responses to intradermal and intranodal mRNA lipoplex vaccination.
As the route of immunization has a dramatic impact on the type of innate immune cells the mRNA lipoplexes encounter and thereby potentially also on the ensuing T cell response, we decided to evaluate the impact of type I IFNs on the cytolytic T cell response to intradermal and intranodal immunization with mRNA lipoplexes. mRNA lipoplexes also instigated a profound type I IFN response to intradermal (Fig. 5a ) and intranodal (Fig. 5c) injection. In terms of T cell immunity, intradermal immunization with mRNA lipoplexes behaved much alike subcutaneous immunization, with the strength of the cytolytic T cell response shifting from near absent in wild type mice to virtually complete in Ifnar -/-mice (Fig. 5b ).
In line with reports of the Thielemans 32 and Sahin 33 groups, intranodal immunization turned out to be by far the most potent route of immunization with strong cytolytic T cell responses now being evident in immunized wild type mice (Fig. 5d) . Nevertheless, even intranodal immunization was aided by IFNAR A c c e p t e d m a n u s c r i p t
Supplementary data
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Materials and methods

Mice
Female wild type C57BL/6 mice were purchased from Janvier (Le Genest Saint Isle, France). OT-I mice carrying a transgenic CD8 + T cell receptor specific for the MHC I-restricted ovalbumin (OVA) peptide SIINFEKL were donated by Dr. Bart Lambrecht from Ghent University (Ghent, Belgium). Ifnar1 
Production of in vitro transcribed mRNA
The pGEM4Z-OVA-A64 and the pGEM4Z-EGFP-A64 plasmids were kindly donated by dr. David
Boczkowski from Duke University (Durham, NY). The pBluescript-luc-A64 plasmid was provided by Dr. Joanna Rejman from Ghent University (Ghent, Belgium). All plasmids were propagated in E. coli competent cells (Stratagene, La Jolla, CA, USA) and purified using endotoxin-free QIAGEN-tip 500 columns (Qiagen, Chatsworth, CA, USA). The pGEM4-OVA-A64 and pGEM4Z-EGFP-A64 plasmids were linearized with SpeI (MBI Fermentas, St Leon-Rot, Germany), whereas the pBluescirpt-luc-A64
A c c e p t e d m a n u s c r i p t plasmid was linearized with DraI (MBI Fermentas, St Leon-Rot, Germany). Linearized plasmids were purified using a PCR purification kit (Qiagen, Venlo, The Netherlands) and RNA was transcribed using the T7 mMessage Machine Kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions. The in vitro transcribed mRNA was purified by lithium chloride precipitation.
Immunizations and injections of mRNA lipoplexes
Subcutaneous immunizations were performed in C57BL/6 mice twice at tail base in a 2 week interval.
According to the experiment 10 or 20 µg of OVA-encoding mRNA was complexed with DOTAP/DOPE lipids in a N/P ratio of 1 (Avanti Polar Lipids, Alabaster, AL, USA) and injected in a total volume of 40 µl of 5% glucose water (Ambion, Life technologies, USA). For intranodal delivery of mRNA, C57BL/6 mice were anesthetized with ketamine (70 mg/kg; Ceva) and xylazine (10 mg/kg; Bayer). The inguinal lymph node was surgically exposed and injected with 10 µg RNA lipoplexes in a total volume of 15 µl. Red blood cells were lysed using ACK red blood cell lysis buffer (BioWhittaker, Wakersville, MD,
A c c e p t e d m a n u s c r i p t
USA) and 2.5 x 10 5 cells were cultured for 24 hours on IFN-γ (Diaclone, Besançon, France) pre-coated 96-well plates in the presence of 10 µg/ml OVA peptides (Anaspec, Fremont, CA, USA). To quantify the amount of OVA-specific CD8 + and CD4 + T cells we pulsed the splenocytes with resp. 10 µg/ml MHC-I and MHC-II OVA peptides. Spots were analyzed according to the manufacturer's instructions using ELISPOT reader.
CD8 + T cell dextramer staining
Mice were immunized twice with 20 µg of DOTAP/DOPE complexed OVA-encoding mRNA as described previously. Five days later, blood samples were taken and red blood cells were removed using A c c e p t e d m a n u s c r i p t
